Bristol-Myers to continue M&A activity, R&D chief says

09/23/2009 | Forbes

Bristol-Myers Squibb will pursue more takeovers after its $2.4 billion acquisition of Medarex, said Elliot Sigal, the company's head of research and development. Bristol-Myers expects about a third of its drug portfolio to come from external sources as it prepares to counteract the effects of the so-called patent cliff.

View Full Article in:

Forbes